uploads///LOE

How Pfizer’s Peri-LOE Products Performed in 2017

By

Feb. 15 2018, Updated 9:00 a.m. ET

PFE’s Peri-LOE products

Pfizer’s (PFE) Peri-LOE products refer to those products that lost patient protection recently or are expected to lose patient protection soon. Pfizer’s Peri-LOE products in the global market include Celebrex, Pristiq, Zyvox Vfend, Revatio, Viagra, Lyrica, and Inspra.

Article continues below advertisement

Celebrex revenue trends

In fiscal 2017, Pfizer’s (PFE) Celebrex generated revenues of $775 million, which is ~6% higher on a YoY (year-over-year) basis. In the US and outside the US (international markets), Celebrex reported revenues of $164 million and $611 million, respectively, compared with $116 million and $617 million in 2016.

In 4Q17, Celebrex reported revenues of $210 million, which is ~15% higher on a YoY basis and 1% lower on a quarter-over-quarter basis.

Celebrex (celecoxib) is an NSAID (nonsteroidal anti-inflammatory drug) used for the treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain, and primary dysmenorrhea.

Some notable NSAIDS in the marketplace include Johnson & Johnson’s (JNJ) Motrin and Bayer’s (BAYZF) Aleve.

Vfend revenue trends

In 2017, Vfend generated revenues of $421 million, which is ~29% higher on a YoY basis. In the US and in international markets Vfend reported revenues of $13 million and $407 million, respectively, for 2017, compared with $31 million and $559 million in 2016.

In 4Q17, Vfend reported revenues of $115 million, which is ~13% lower on a YoY basis and 19% growth quarter-over-quarter.

Vfend (Voriconazole) is an antifungal agent indicated in individuals 12 years and older for the treatment of different fungal infections.

Article continues below advertisement

Pristiq revenue trends

In 2017, Pristiq reported revenues of $303 million, compared with $732 million in 2016. In 2017, in the US and in international markets, Pristiq reported revenues of $133 million and $170 million, respectively, compared with $578 million and $154 million in 2016.

In 4Q17, Pristiq reported revenues of $73 million, which is ~61% lower on a YoY basis but 6% higher quarter-over-quarter.

Pristiq (desvenlafaxine) is used for the treatment of major depressive disorders. In the marketplace, Pristiq’s peers include Allergan’s (AGN) Viibryd, Eli Lilly’s (LLY) Prozac, and Otsuka America Pharmaceuticals’ Abilify.

Zyvox revenue trends

In 2017, Zyvox reported revenues of $281 million, which is ~33% lower on a YoY basis. In 2017, in the US and in international markets, Zyvox reported revenues of $15 million and $266 million, respectively, compared with $66 million and $355 million in 2016.

In 4Q17, Zyvox reported revenues of $61 million, which is ~29% lower on a YoY basis and 10% lower quarter-over-quarter.

Revatio revenue trends

In 2017, Revatio generated revenues of $252 million, which is ~12% lower on a YoY basis. In 2017, in the US and in international markets, Revatio reported revenues of $119 million and $133 million, compared with $98 million and $187 million in 2016.

In 4Q17, Revatio reported revenues of $62 million, which is ~14% lower on a YoY basis but 7% higher on a quarter-over-quarter basis.

Revatio (sildenafil) is used for the treatment of pulmonary arterial hypertension.

Now let’s take a closer look at the performance of Pfizer’s sterile injection pharmaceuticals in 4Q17 and 2017.

Advertisement

More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.